CannabisNewsBreaks Archive - Page 4 of 217

WednesdayMay 01, 2024 2:19 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share; the shares and warrants were originally issued in October 2023 and February 2024, respectively. The company noted that following this exercise, there are no remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. According…

ThursdayApr 18, 2024 1:56 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. “We are privileged to welcome someone of Dr. Morgan’s…

TuesdayApr 16, 2024 3:42 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

TuesdayApr 16, 2024 1:31 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

MondayApr 08, 2024 1:12 pm

CannabisNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Approved as US Government Vendor, Proprietary TRACER 1000 Listed on GSA

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, have announced that its TRACER 1000(TM) is now listed in the U.S. General Services Administration (“GSA”) IT Schedule 70, making the company an approved U.S. government vendor. The device can be found under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290. According to the announcement, IT Schedule 70 is a long-term contract issued to commercial technology vendors that allows sales to the U.S. government, one of the largest buyers of goods and services in the world. A high-performance laboratory instrument of ruggedized mass…

ThursdayMar 28, 2024 3:25 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH technology including its new foray into GLP-1 drugs… This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage…

WednesdayMar 27, 2024 2:45 pm

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Marks Significant Progress Across Its Diverse Portfolio

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a leading entity in the cannabis and agricultural technology sectors, today announced remarkable advancements across its operations. MedCana is poised for significant growth and profitability with its subsidiaries in the final stages of negotiations to determine varietals to export to Europe and Australia, and Eko2o S.A.S. rapidly expanding its reach within the agricultural industry. MedCana’s strategic foray into cannabis production is nearing fruition, with operations gearing up to meet the stringent quality and regulatory standards of the European and Australian markets. In addition, Eko2o S.A.S., a majority-controlled subsidiary of MedCana, is making notable…

ThursdayMar 21, 2024 2:00 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on Apr. 8-9, 2024. Lexaria CEO Chris Bunka will be presenting at the event, with his presentation scheduled to begin at 10:30 a.m. ET on Tuesday, Apr. 9. Bunka will discuss the company’s recent discovery of enhanced performance of glucagon-like-peptide-1 (“GLP-1”) drugs utilizing DehydraTECH. The presentation will also cover the highly anticipated upcoming animal and clinical studies in humans to more thoroughly evaluate the impact of DehydraTECH processing on…

ThursdayMar 21, 2024 1:38 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to comply with NASDAQ’s minimum bid price requirement for the continued listing on the NASDAQ Capital Market. InMed received a letter from the exchange notifying it of the extended deadline, which will now be Sept. 16, 2024. According to the announcement, the compliance issues have no immediate effect on the listing or trading of the InMed Pharmaceuticals’ ordinary shares, which will continue to trade on the NASDAQ Capital Market. “NASDAQ's determination is based on…

ThursdayMar 14, 2024 3:06 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executive leadership team. Cabatuan brings more than 15 years of corporate finance and operations experience in the life sciences industry. Most recently, he served as senior vice president of finance and operations at Rain Oncology Inc., a late-stage precision oncology biotech company. In that position, he was pivotal in building and leading the company’s financial organization, resulting in significant growth…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 512.354.7000

CannabisNewsBreaks